NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

CompletedPhase 1

Sponsor: Pfizer

Conditions: Arthritis, Rheumatoid

Interventions: SBI-087, SBI-087, SBI-087, SBI-087

Countries: Japan

The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.

Eligibility overview

Sex: ALL

Age: 20 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Must meet American College of Rheumatology criteria for rheumatoid arthritis with functional class I to III.
* Rheumatoid arthritis disease onset at \>16 years of age and duration of disease at least 6 months.
* Men or women of nonchildbearing potential (WONCBP), aged 20 to 70 years, inclusive at the screening visit.

Exclusion Criteria:

* Any significant health problems other than rheumatoid arthritis.
* Treatment of greater than 10 mg of prednisone per day.
* Therapy with immunosuppressants within 6 months before study day 1

Locations (7)

Ehime, Japan
Fukui, Japan
Kanagawa, Japan
Miyagi, Japan
Ōita, Japan
Shizuoka, Japan
Tokyo, Japan